MA41038B1 - Composés d'aminopyridyloxypyrazole - Google Patents

Composés d'aminopyridyloxypyrazole

Info

Publication number
MA41038B1
MA41038B1 MA41038A MA41038A MA41038B1 MA 41038 B1 MA41038 B1 MA 41038B1 MA 41038 A MA41038 A MA 41038A MA 41038 A MA41038 A MA 41038A MA 41038 B1 MA41038 B1 MA 41038B1
Authority
MA
Morocco
Prior art keywords
compounds
cancer
daminopyridylooxpyrazole
tgfpri
glioblastoma
Prior art date
Application number
MA41038A
Other languages
English (en)
Other versions
MA41038A (fr
Inventor
Craig D Wolfangel
Douglas W Beight
David A Coates
Sajan Joseph
William T Mcmillen
Saravanan Parthasarathy
Huaxing Pei
Jason Scott Sawyer
Gaiying Zhao
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA41038A publication Critical patent/MA41038A/fr
Publication of MA41038B1 publication Critical patent/MA41038B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne de nouveaux composés daminopyridylooxpyrazole qui inhibent l'activité du récepteur 1 du facteur du croissance transformant beta (tgfpri), des compositions pharmaceutiques comprenant les composés et des procédés d'utilisation des composés pour traiter le cancer du colon,mélanome carcinomehépatocellulaire, cancer rénal, glioblastome, cancer du pancréas, syndrome myélodysplasique, cancer du poumon et cancer gastrique et/ou la fibrose, de préference cirrhose du foie et maladie rénale chronique.
MA41038A 2014-10-07 2015-09-30 Composés d'aminopyridyloxypyrazole MA41038B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462060724P 2014-10-07 2014-10-07
PCT/US2015/053098 WO2016057278A1 (fr) 2014-10-07 2015-09-30 Composés d'aminopyridyloxypyrazole
EP15777845.7A EP3204377B1 (fr) 2014-10-07 2015-09-30 Composés d'aminopyridyloxypyrazole

Publications (2)

Publication Number Publication Date
MA41038A MA41038A (fr) 2017-08-16
MA41038B1 true MA41038B1 (fr) 2018-10-31

Family

ID=54266692

Family Applications (1)

Application Number Title Priority Date Filing Date
MA41038A MA41038B1 (fr) 2014-10-07 2015-09-30 Composés d'aminopyridyloxypyrazole

Country Status (42)

Country Link
US (1) US9617243B2 (fr)
EP (1) EP3204377B1 (fr)
JP (1) JP6043894B2 (fr)
KR (1) KR101921847B1 (fr)
CN (1) CN106795139B (fr)
AP (1) AP2017009836A0 (fr)
AR (1) AR102003A1 (fr)
AU (1) AU2015328553C1 (fr)
BR (1) BR112017005453B1 (fr)
CA (1) CA2961262C (fr)
CL (1) CL2017000765A1 (fr)
CO (1) CO2017002233A2 (fr)
CR (1) CR20170072A (fr)
CY (1) CY1120903T1 (fr)
DK (1) DK3204377T3 (fr)
DO (1) DOP2017000090A (fr)
EA (1) EA031830B1 (fr)
EC (1) ECSP17021097A (fr)
ES (1) ES2700376T3 (fr)
GT (1) GT201700067A (fr)
HR (1) HRP20181797T1 (fr)
IL (1) IL250543B (fr)
JO (1) JO3336B1 (fr)
LT (1) LT3204377T (fr)
MA (1) MA41038B1 (fr)
MX (1) MX367360B (fr)
MY (1) MY190541A (fr)
NZ (1) NZ729800A (fr)
PE (1) PE20170662A1 (fr)
PH (1) PH12017500635B1 (fr)
PL (1) PL3204377T3 (fr)
PT (1) PT3204377T (fr)
RS (1) RS58094B1 (fr)
SG (1) SG11201702481UA (fr)
SI (1) SI3204377T1 (fr)
SV (1) SV2017005411A (fr)
TN (1) TN2017000046A1 (fr)
TR (1) TR201816415T4 (fr)
TW (1) TWI582083B (fr)
UA (1) UA118807C2 (fr)
WO (1) WO2016057278A1 (fr)
ZA (1) ZA201701175B (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015089800A1 (fr) 2013-12-19 2015-06-25 Eli Lilly And Company Composés fluorophényl-pyrazole
AU2014373773C1 (en) 2014-01-01 2019-06-27 Medivation Technologies Llc Compounds and methods of use
JP6626885B2 (ja) * 2014-10-31 2019-12-25 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 新しいピリジニルオキシ及びフェニルオキシピラゾリル化合物
EP3518926A1 (fr) 2016-09-30 2019-08-07 Eli Lilly and Company Utilisation de 2-{4-[(4-{[1-cyclopropyl-3-tétrahydro-2h-pyrane-4-yl)-1h-pyrazole-4-yl]oxy}pyridine-2-yl)amino]pyridine-2-yl}propane-2-ol pour le traitement du cancer
JOP20190080A1 (ar) * 2016-10-14 2019-04-11 Bayer Pharma AG مركبات مشتقة من 6-(1h-بيرازول-1-يل) بيريميدين-4- أمين مستبدل واستخداماتها
US11124509B2 (en) 2017-03-23 2021-09-21 Clavius Pharmaceuticals, LLC. Tri-substituted imidazoles for the inhibition of TGF beta and methods of treatment
WO2019013790A1 (fr) * 2017-07-12 2019-01-17 Curza Global, Llc Composés antimicrobiens et leurs utilisations
CN107540672A (zh) * 2017-10-10 2018-01-05 牡丹江医学院 一种治疗肝硬化的药物及其合成方法
CN107892687B (zh) * 2018-01-21 2018-08-24 广东莱恩医药研究院有限公司 一种2-乙酸酯咪唑类化合物及其在防治骨质疏松药物中的应用
CA3103771A1 (fr) * 2018-06-18 2019-12-26 Janssen Pharmaceutica Nv 6-aminopyridin-3-yl pyrazoles en tant que modulateurs de roryt
CN112867724A (zh) 2018-07-23 2021-05-28 广州噢斯荣医药技术有限公司 二膦酸盐药物缀合物
CN112512597A (zh) 2018-07-26 2021-03-16 大日本住友制药肿瘤公司 用于治疗与acvr1表达异常相关的疾病的方法以及用于此的acvr1抑制剂
WO2020041562A1 (fr) * 2018-08-22 2020-02-27 Clavius Pharmaceuticals, Llc Imidazoles substitués pour l'inhibition de tgf-bêta et méthodes de traitement
WO2020078402A1 (fr) * 2018-10-18 2020-04-23 南京圣和药业股份有限公司 COMPOSÉ SERVANT D'INHIBITEUR DE TGF-β R1 ET SON UTILISATION
CN112839946B (zh) * 2018-10-31 2022-04-12 江苏奥赛康药业有限公司 作为TGF-βR1激酶抑制剂的双环吡唑类化合物
WO2020103817A1 (fr) * 2018-11-20 2020-05-28 南京圣和药业股份有限公司 INHIBITEUR DE TGF-βR1 ET SON UTILISATION
BR112021007006A2 (pt) * 2018-12-27 2021-08-10 Nexys Therapeutics, Inc. derivados de (piridin-2-il)amina como inibidores de tgf-beta r1(alk5) para o tratamento de câncer
US20200323851A1 (en) * 2019-01-10 2020-10-15 Tolero Pharmaceuticals, Inc. Alk5 inhibitors for treating myelodysplastic syndrome
KR20210118891A (ko) 2019-01-24 2021-10-01 지앙수 아오사이캉 파마수티칼 씨오., 엘티디. TGF-β R1 키나아제 억제제로서의 5-(4-피리딜옥시)피라졸 화합물
WO2020258006A1 (fr) * 2019-06-25 2020-12-30 Inventisbio Shanghai Ltd. Composés hétérocycliques, leurs procédés de préparation et leurs méthodes d'utilisation
CN112694477B (zh) * 2019-10-22 2024-02-06 四川科伦博泰生物医药股份有限公司 吡唑并环类化合物，包含其的药物组合物，其制备方法及其用途
CN114728980A (zh) * 2019-12-23 2022-07-08 江苏先声药业有限公司 吡唑类化合物
CN111116565B (zh) * 2020-04-01 2020-07-14 中科利健制药(广州)有限公司 2-芳基-4-（4-吡唑氧基）吡啶类化合物、其制备方法、药物组合物与应用
CN111303135A (zh) * 2020-04-01 2020-06-19 中科利健制药(广州)有限公司 4-（4-吡唑氧基）喹啉类化合物、其制备方法、药物组合物与应用
WO2021204626A1 (fr) 2020-04-06 2021-10-14 Almirall, S.A. Composés hétéroaryle substitués par aryle et hétéroaryle-carboxamide utiles en tant qu'inhibiteurs de tyk2
CN113698395B (zh) * 2020-05-22 2023-12-08 赛诺哈勃药业（成都）有限公司 转化生长因子受体拮抗剂、其制备方法和应用
CN114867723B (zh) * 2020-07-23 2023-05-30 江苏奥赛康药业有限公司 作为TGF-βR1抑制剂的吡啶氧基连吡唑类化合物的盐型、晶型以及其药物组合物
WO2023182780A1 (fr) * 2022-03-22 2023-09-28 오토텔릭바이오 주식회사 Composé dérivé de thiazole et ses utilisations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03010630A (es) 2001-05-24 2004-03-09 Lilly Co Eli Nuevos derivados de pirrol como agentes farmaceuticos.
UA80571C2 (en) 2002-11-22 2007-10-10 Lilly Co Eli Quinolinyl-pyrrolopyrazoles
GB0313915D0 (en) * 2003-06-16 2003-07-23 Smithkline Beecham Corp Compounds
UY31281A1 (es) * 2007-08-13 2009-03-31 Aminas, benzamidas y sulfonamidas {[4-(5,6-dimetil-2-piridin-2-il-piridin-3-il) oxipiridin-2-il]amino} sustituidas, sus sales farmacéuticamente aceptables, composiciones contenniéndolas y aplicaciones.
US8080568B1 (en) 2010-06-29 2011-12-20 Ewha University - Industry Collaboration Foundation 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors
US20140296248A1 (en) 2011-04-04 2014-10-02 Stichting het Nederlands Kanker Instiuut-Antoni van Leeuwenhoek ziekenhuis Methods and compositions for predicting resistance to anticancer treatment
TW201329067A (zh) * 2011-12-08 2013-07-16 Amgen Inc 作為ｇｋａ活化劑之脲化合物
WO2015089800A1 (fr) 2013-12-19 2015-06-25 Eli Lilly And Company Composés fluorophényl-pyrazole

Also Published As

Publication number Publication date
NZ729800A (en) 2018-07-27
TR201816415T4 (tr) 2018-11-21
US9617243B2 (en) 2017-04-11
EP3204377A1 (fr) 2017-08-16
CO2017002233A2 (es) 2017-05-31
CY1120903T1 (el) 2020-05-29
WO2016057278A1 (fr) 2016-04-14
BR112017005453A2 (pt) 2017-12-12
KR20170045348A (ko) 2017-04-26
KR101921847B1 (ko) 2018-11-23
TWI582083B (zh) 2017-05-11
BR112017005453A8 (pt) 2018-04-24
SV2017005411A (es) 2017-04-21
JP2016535745A (ja) 2016-11-17
HRP20181797T1 (hr) 2018-12-28
AR102003A1 (es) 2017-01-25
JP6043894B2 (ja) 2016-12-14
TW201623282A (zh) 2016-07-01
TN2017000046A1 (en) 2018-07-04
MA41038A (fr) 2017-08-16
AU2015328553A1 (en) 2017-03-09
CL2017000765A1 (es) 2017-12-15
CN106795139A (zh) 2017-05-31
CR20170072A (es) 2017-05-12
JO3336B1 (ar) 2019-03-13
PH12017500635A1 (en) 2017-09-25
AP2017009836A0 (en) 2017-03-31
SG11201702481UA (en) 2017-04-27
ES2700376T3 (es) 2019-02-15
MX2017004457A (es) 2017-06-19
EP3204377B1 (fr) 2018-09-26
MY190541A (en) 2022-04-27
CA2961262A1 (fr) 2016-04-14
UA118807C2 (uk) 2019-03-11
GT201700067A (es) 2019-10-10
LT3204377T (lt) 2018-12-27
AU2015328553B2 (en) 2018-04-12
RS58094B1 (sr) 2019-02-28
EA201790476A1 (ru) 2017-08-31
PT3204377T (pt) 2018-12-19
CN106795139B (zh) 2019-08-09
DOP2017000090A (es) 2017-04-30
DK3204377T3 (en) 2018-11-26
IL250543A0 (en) 2017-03-30
PE20170662A1 (es) 2017-05-26
MX367360B (es) 2019-08-16
SI3204377T1 (sl) 2018-11-30
ECSP17021097A (es) 2018-02-28
BR112017005453B1 (pt) 2022-12-06
IL250543B (en) 2020-06-30
US20160096823A1 (en) 2016-04-07
EA031830B1 (ru) 2019-02-28
CA2961262C (fr) 2019-10-22
PH12017500635B1 (en) 2017-09-25
PL3204377T3 (pl) 2019-02-28
ZA201701175B (en) 2019-01-30
AU2015328553C1 (en) 2018-11-15

Similar Documents

Publication Publication Date Title
MA41038B1 (fr) Composés d'aminopyridyloxypyrazole
EP3607074A4 (fr) Réduction ou élimination de réponses immunitaires à des protéines thérapeutiques administrées par voie non intraveineuse, par exemple par voie sous-cutanée
EA201792047A1 (ru) Новые соединения
PH12019502576A1 (en) Bis-octahydrophenanthrene carboxamides and protein conjugates thereof
MX2017014908A (es) Proteinas de union triespecificas y metodos de uso.
MX2018015271A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
MX2022003891A (es) Anticuerpos anti-muc16 y sus usos.
MX2017013075A (es) Conjugados de farmaco que comprenden anticuerpos contra claudina 18.2.
SG10201909796PA (en) Chemosensory receptor ligand-based therapies
MX2018015275A (es) Compuestos de tetrahidropiranilcarbonil-2,3-dihidro-1h-indol para tratar cancer.
MX2021012205A (es) Anticuerpos de cadena pesada que se unen al psma.
NZ737399A (en) Ccr2 modulators
TW200714290A (en) Anti-M-CSF antibody compositions having reduced levels of endotoxin
MX2022005404A (es) Compuestos de fijación a il-2r e il-7r dual.
MX2014004074A (es) Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2.
MY185593A (en) Cortistatin analogues for the treatment of inflammatory and/or immune diseases
EA201791227A1 (ru) РЕЖИМ ДОЗИРОВАНИЯ АНТАГОНИСТОВ MAdCAM
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
MX2019009847A (es) Proteínas que se unen a cd123, nkg2d y cd16.
MA43250B1 (fr) Composés d'oxadiazaspiro pour le traitement de l'abus et la dépendance aux drogues
MA43158B1 (fr) Composés oxa-diazadispiro possédant une activité contre la douleur
PH12019502717A1 (en) Recombinant robo2 proteins, compositions, methods and uses thereof
MX2022000317A (es) Anticuerpos altamente potentes que se unen al receptor de muerte 4 y al receptor de muerte 5.
MA44558B1 (fr) Dérivé du glucagon, conjugué de celui-ci, composition le comprenant et utilisation thérapeutique de celui-ci
PL426662A1 (en) Composition for intravitreal administration of therapeutic protein